Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus

Current Diabetes Reports

Volumn 9, Issue 3, 2009, Pages 200-207

  Cusi, Kenneth ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; FATTY ACID;

ADIPOSE TISSUE; CELL FUNCTION; DISEASE COURSE; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SKELETAL MUSCLE;

DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIVER; MUSCLES;

EID: 66149093535     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0033-6     Document Type: Review

References (50)

1. Cusi K: The epidemic of type 2 diabeIes mellitus: its links to obesity, insulin resistance and lipotoxicity. In Diabetes and Exercise. Edited by Regensteiner JG, Reusch JE, Stewart K, Veves A. Totowa, NJ: Humana Press; 2009 (in press).
2. Wyatt, Wyatt SB, Winters KP, Dubbert PM: Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 2006, 331:166-174.
3. Cusi K, DeFronzo R: Non-insulin dependent diabetes mellitus. In Handbook of Physiology. The Endocrine Pancreas and Regulation of Metabolism. Edited by Jefferson LS, Cherrington AD. Oxford, UK: Oxford University Press, 2001:1115-1168.
4. Vaag A, Poulsen P: Twins in metaboliW and diabetes research: what do they tell us? Curr Opin Clin Nutr Metab Care 2007, 10:591-596.
5. Warram J, Krolewski A, Kahn C: Slow glucose removal rate and hyperinsulinemia precede the development of type 2 diabetes in offspring of diabetic parents. Ann Intern Med 1990, 113:909-915.
6. Buchanan TA: (How) can we prevent type 2 diabetes? Diabetes 2007, 56:1502-1507.
7. Gulli G, Ferrannini E, Stern M, et al.: The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 1992, 41:1575-1586.
8. Pratipanawatr W, Pratipanawatr T, Cusi K, et al.: Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation. Diabetes 2001, 50:2572-2578.
9. Kashyap S, Belfort R, Gastaldelli A, et al.: A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003, 52:2461-2474.
10. Kashyap SR, Belfort R, Berria R, et al.: Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrin Metab 2004, 287:E537-E546.
11. Mathew M, Tay C, Belfort R, et al.: A 48-hour elevation in plasma FFA, but not hyperglycemia, impairs insulin secretion in lean Mexican-American subjects genetically predisposed to T2DM. Diabetes 2007, 56(Suppl 1):A674.
12. Petersen KF, Dufour S, Befroy D, et al.: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004, 350:664-671.
13. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997, 46:3-10.
14. Kelley D, Mandarino L: Fuel selection in human skeletal muscle in insulin resistance. A reexamination. Diabetes 2000, 49:677-683.
15. Morino K, Petersen K, Shulman G: Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006, 55:S9-S15.
16. Storgaard H, Jensen C, Bjornholm M, et al.: Dissociation between fat-induced in vivo insulin resistance and proximal insulin signaling in skeletal muscle in men at risk for type 2 diabetes. J Clin Endocrinol Metab 2004, 89:1301-1311.
17. Belfort R, Mandarino L, Kashyap S, et al.: Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 2005, 54:1640-1648.
18. Virkamaki A, Korsheninnikova E, Seppala-Lindroos A, et al.: Intramyocellular lipid Is associated with resistance to in vivo Insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 2001, 50:2337-2343.
19. Thamer C, Machann J, Bachmann O, et al.: Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivity. J Clin Endocrinol Metab 2003, 88:1785-1791.
20. Cusi K: Evolving concepts in lipotoxicity. In The American Association for the Study of Liver Disease Postgraduate Course. Alexandria, VA: American Association for the Study of Liver Disease; 2008:72-84.
21. Szendroedi J, Roden M: Ectopic lipids and organ function. Curr Opin Lipidol 2009, 20:50-56.
22. Reyna SM, Ghosh S, Tantiwong P, et al.: Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 2008, 57:2595-2602.
23. Patti ME, Butte AJ, Crunkhorn S, et al.: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 2003, 100:8466-8471.
24. De Filippis E, Alvarez G, Berria R, et al.: Insulin-resistant muscle is exercise resistant: Evidence for reduced response of nuclear-encoded mitochondrial genes to exercise. Am J Physiol Endocrinol Metab 2008, 294:E607-E614.
25. Richardson DK, Kashyap S, Bajaj M, et al.: Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. J Biol Chem 2005, 280:10290-10297.
26. Befroy DE, Petersen KF, Dufour S, et al.: Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes 2007, 56:1376-1381.
27. Cusi K, Kashyap S, Belfort R, et al.: Effects on insulin secretion and action of short-term reduction of plasma free fatty acids with acipimox in non-diabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292:E1775-E1781.
28. Cusi K: Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2009, 16:141-149.
29. Kashyap S, Belfort R, Cersosimo E, et al.: Chronic low-dose lipid infusion in healthy patients induces markers of endothelial activation independent of its metabolic effects. J Cardiometab Syndr 2008, 3:141-146.
30. Semple R, Sleigh A, Murgatroyd P, et al.: Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009, 119:315-322.
31. Tay C, Belfort R, Mathew M, Cusi K: A 2-day lipid or combined lipid-glucose infusion reproduce in healthy subjects the metabolic abnormalities seen in the metabolic syndrome. Diabetes 2006, 55(Suppl 1):A66.
32. Brassard P, Frisch F, Lavoie F, et al.: Impaired plasma nonesterified fatty acid tolerance is an early defect in the natural history of type 2 diabetes. J Clin Endocrinol Metab 2008, 93:837-844.
33. Civitarese A, Jenkinson C, Richardson D, et al.: Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes. Diabetologia 2004, 47:816-820.
34. Nolan C, Leahy J, Delghingaro-Augusto V, et al.: Beta cell compensation for insulin resistance in Zucker fatty rats: Increased lipolysis and fatty acid signalling. Diabetologia 2006, 49:2120-2130.
35. Mathew M, Darland C, Kumar P, et al.: Effect of obesity on insulin secretion in response to a 48-hour physiological increase in plasma FFA in Mexican-American subjects genetically predisposed to type 2 diabetes. Diabetes 2008, 56(Suppl 1):A389.
36. Gastaldelli A, Ferrannini E, Miyazaki Y, et al.: Beta cell dysfunction and glucose intolerance: Results from the San Antonio metabolism (SAM) study. Diabetologia 2004, 47:31-39.
37. Unger R, Zhou Y: Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 2001, 50(Suppl 1):S118-S121.
38. Nolan CJ, Madiraju MS, Delghingaro-Augusto V, et al.: Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 2006, 55(Suppl 2):S16-S23.
39. Maedler K: Beta cells in type 2 diabetes-a crucial contribution to pathogenesis. Diabetes Obesity Metabolism 2008, 10:408-420.
40. Delghingaro-Augusto V, Nolan C, Gupta D, et al.: Islet beta cell failure in the 60% pancreatectomised obese hyperlipidaemic Zucker fatty rat: severe dysfunction with altered glycerolipid metabolism without steatosis or a falling beta cell mass. Diabeteologia 2009 Mar 18 (Epub ahead of print).
41. Amery CM, Round RA, Smith JM, Nattrass M: Elevation of plasma fatty acids by ten-hour intralipid infusion has no effect on basal or glucose-stimulated insulin secretion in normal man. Metabolism 2000, 49:450-454.
42. Balent B, Goswami G, Goodloe G, et al.: Acute elevation of NEFA causes hyperinsulinemia without effect on insulin secretion rate in healthy human subjects. Ann NY Acad Sci 2002, 967:535-543.
43. Storgaard H, Jensen C, Vaag A, et al.: Insulin secretion after short- and long-term low-grade free fatty acid infusion in men with increased risk of developing type 2 diabetes. Metabolism 2003, 52:885-894.
44. Paolisso G, Gambardella A, Amato L, et al.: Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 1995, 38:1295-1299.
45. Carpentier A, Mittelman SD, Bergman RN, et al.: Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol Endocrinol Metab 1999, 276:E1055-E1066.
46. Boden G, Chen X: Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995, 96:1261-1268.
47. Magnan C, Collins S, Berthault MF, et al.: Lipid infusion lowers sympathetic nervous activity and leads to increased beta-cell responsiveness to glucose. J Clin Invest 1999, 103:413-419.
48. Carpentier A, Mittelman SD, Bergman RN, et al.: Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 2000, 49:399-408.
49. Mathew M, Kumar P, Ali R, et al.: Insulin secretion in patients with impaired glucose tolerance (IGT) is readily susceptible to FFA-induced lipotoxicity. Diabetes 2008, 57(Suppl 1):A153.
50. Cusi K, Maezono K, Osman A, et al.: Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000, 105:311-320.